Comprehensive registry of esophageal cancer in Japan, 2014.
Comprehensive registry of esophageal cancer in Japan, 2014.
复制标题
2014年，日本食管癌的综合注册表。
DOI：
10.1007/s10388-021-00879-1
复制
发表时间：
2022-01
期刊：
影响因子：
--
通讯作者：
Registration Committee for Esophageal Cancer of the Japan Esophageal Society
中科院分区：
文献类型：
--
作者：
Watanabe M;Toh Y;Ishihara R;Kono K;Matsubara H;Murakami K;Muro K;Numasaki H;Oyama T;Ozawa S;Saeki H;Tanaka K;Tsushima T;Ueno M;Uno T;Yoshio T;Usune S;Takahashi A;Miyata H;Registration Committee for Esophageal Cancer of the Japan Esophageal Society
日本食管学会（JES）食管癌登记委员会每年收集患者的特征、治疗和结局。我们分析了2014年访问参与医院的患者数据。我们使用基于网络的数据收集系统，使用国家临床数据库收集数据。我们使用JES的日本食管癌分类第10版和国际癌症控制联盟（UICC）的TNM分类第7版进行癌症分期。日本344家机构共登记9026例。鳞癌和腺癌分别占87.9%和7.1%。内镜切除、同步放化疗、单纯放疗和食管切除术的5年生存率分别为87.1%、33.7%、25.3%和59.3%。食管切除术5204例。关于用于食管切除术的入路，48.1%的病例采用胸腔镜治疗。手术死亡率（术后30天内）为0.75%，住院死亡率为2.0%。JES系统的生存曲线对临床分期和病理分期均有很好的区分能力。在UICC系统中，pStage IV的生存率优于IIIC，因为pStage IV包括锁骨上淋巴结转移（M1 LYM）的患者。我们希望这份报告有助于改善日本食管癌诊断和治疗的各个方面。
The registration committee for esophageal cancer in the Japan Esophageal Society (JES) has collected the patients' characteristics, treatment, and outcomes annually. We analyzed the data of patients who had visited the participating hospitals in 2014. We collected the data with a web-based data collection system using the National Clinical Database. We used the Japanese Classification of Esophageal Cancer 10th edition by JES and the TNM classification 7th edition by the Union of International Cancer Control (UICC) for cancer staging. A total of 9026 cases were registered from 344 institutions in Japan. Squamous cell carcinoma and adenocarcinoma accounted for 87.9% and 7.1%, respectively. The 5-year survival rates of patients treated using endoscopic resection, concurrent chemoradiotherapy, radiotherapy alone, and esophagectomy were 87.1%, 33.7%, 25.3%, and 59.3%, respectively. Esophagectomy was performed in 5204 cases. Concerning the approach used for esophagectomy, 48.1% of the cases were treated thoracoscopically. The operative mortality (within 30 days after surgery) was 0.75%, and the hospital mortality was 2.0%. The survival curves showed an excellent discriminatory ability both in the clinical and pathologic stages by the JES system. The survival of pStage IV was better than IIIC in the UICC system, because pStage IV included the patients with supraclavicular lymph-node metastasis (M1 LYM). We hope that this report contributes to improving all aspects of diagnosing and treating esophageal cancer in Japan.
影响因子：
2.4
作者：
Takubo, Kaiyo;Makuuchi, Hiroyasu;Isono, Kaichi
通讯作者：
Isono, Kaichi